UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 1429, 2016

~~21ST~~21st CENTURY ONCOLOGY

HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)
333-170812		26-1747745
(Commission File Number)		(I.R.S. Employer Identification No.)

Delaware

(State or Other Jurisdiction of Incorporation)

333-170812		26-1747745
(Commission File Number)		(I.R.S. Employer Identification No.)

2270 Colonial Boulevard Fort Myers, Florida		33907
(Address of Principal Executive Offices)		(Zip Code)

(239) 931-7254
(Registrant’s Telephone Number, including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 25.02. ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On November 1429, 2016, Joseph Biscardi, the Senior Vice President, Assistant Treasurer, Controller, Chief Accounting Officer and principal accounting officer of 21st Century Oncology Holdings, Inc. (the “Company”), ~~issued~~informed athe ~~press~~Company ~~release~~that ~~announcing~~he ~~its~~will ~~financial~~resign ~~results~~from ~~for~~those ~~the~~positions, ~~third~~effective ~~quarter~~as ~~and~~of ~~nine months ended September~~December 3023, 2016. ALeAnne ~~copy~~M. ofStewart, the ~~press~~Company’s ~~release~~Chief isFinancial ~~attached~~Officer, ~~hereto~~will asassume ~~Exhibit 99.1~~the ~~and~~additional isrole ~~incorporated~~of ~~herein~~principal byaccounting ~~reference~~officer until a permanent replacement is appointed.

~~The information in this item~~ 2.02, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

~~Item 9.01. Financial Statements and Exhibits.~~SIGNATURES

~~(d) Exhibits~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit Number		Description
	21st CENTURY ONCOLOGY HOLDINGS, INC.
99.1		Press Release dated November 14, 2016.
Date: December 5, 2016	By:	/s/ LeAnne M. Stewart
		Name:	LeAnne M. Stewart
		Title:	Chief Financial Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	21st CENTURY ONCOLOGY HOLDINGS, INC.
Date: November 14, 2016	By:	/s/ LEANNE M. STEWART_
		Name: LeAnne M. Stewart
		Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release dated November 14, 2016.

Filing Compare · 21st Century Oncology Holdings, Inc.